Introducing Fetch™: Our AI Engine That Optimizes Cancer Therapies for Dogs

We’ve always believed that dogs deserve the most advanced medical care possible. Today, we're excited to introduce Fetch™, our proprietary AI engine that is already transforming how we approach cancer treatment for dogs.

Cancer is the leading cause of death for dogs, with over 6 million dogs in the U.S. being diagnosed each year. One of the biggest challenges in treating cancer is its complexity, as cancer can vary genetically between dogs, even those with the same type of cancer. This makes it difficult to use a one-size-fits-all treatment approach, leaving millions of pet owners and veterinarians in search of more effective, personalized options.

What makes Fetch™ unique is its ability to analyze two billion data points (and growing) from the world's largest clinico-genomic canine cancer database. By examining nearly 6,000 real-world canine cancer cases, Fetch™ uncovers complex connections between genetic profiles and targeted therapies that were previously undetectable. This enables Fetch™ to predict the most effective therapies for individual dogs with remarkable precision.

"This first-in-class approach is transformative," explained Professor James Zou, a leading researcher in AI for healthcare at Stanford University who helped develop Fetch.  "Traditional targeted therapies focus on specific genetic markers, while Fetch can uncover new patterns that expand the applicability of these treatments.”

Fetch™ is already showing its potential to improve outcomes for dogs. Our recently granted patent—the first to use AI to determine canine cancer treatment protocols—covers a targeted therapy and biomarker for canine bladder cancer. This patent underscores how Fetch™ is not only identifying new treatment opportunities but also delivering tangible results.

"Dogs are beloved family members, and they deserve access to personalized cancer care with a level of precision that was previously impossible," said Christina Lopes, CEO and Founder of FidoCure.

As the pet industry continues to grow, with projections reaching $500 billion by 2030, FidoCure is uniquely positioned at the intersection of AI, oncology, and veterinary care to make a lasting impact. Our mission remains clear: to provide dogs with cancer the same level of precision care that has transformed human oncology.